Your session is about to expire
← Back to Search
Vaccine + Pembrolizumab for Cancer
Study Summary
This trial is testing a new cancer treatment that uses a modified virus to help the body build an immunity to kill tumor cells, in combination with an antibody that targets certain cells to block tumor growth.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must have enough neutrophils in your blood, at least 1,500 per microliter.You have had an allergic reaction to egg proteins in the past.You have an ongoing autoimmune disease or need to take corticosteroids for your condition, with exceptions for vitiligo and type I diabetes.If you have a history of heart problems, or if tests show problems with your heart, you can't participate in the study.You have a history of a weakened immune system, such as having an organ transplant or HIV.You have a certain amount of p53 protein in your tumor or a specific p53 gene mutation. If you have received p53-based vaccines before, you can still participate.You should be able to perform daily activities without needing help.Your kidneys must be working well, and your blood creatinine levels must be within a certain range.You must have a certain amount of platelets in your blood.You have received a specific type of treatment called anti-PD-1 or anti-PDL-1 before.People with certain types of cancer, such as lung, head and neck, liver, kidney, skin, bladder, breast, and colon cancer, can participate in the screening.If you have advanced solid tumors, you must have already tried and not responded well to at least one type of standard treatment, or you have chosen not to have standard treatment.Your hemoglobin level must be higher than 9 grams per deciliter.Your bilirubin levels must be within a certain range.Your AST and ALT levels in the blood must be within a certain range, unless you have evidence of liver metastasis, in which case they can be slightly higher.You are currently taking systemic corticosteroids, but nasal corticosteroids, inhaled steroids, adrenal replacement steroids, and topical steroids are allowed.
- Group 1: Treatment (p53MVA, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available slots left in this investigation?
"Currently, this trial is not seeking new participants. It was initially listed on the 14th of June 2016 and last modified on March 17th 2022. For those looking for alternative studies, presently there are 9777 trials that are actively recruiting patients with melanoma and 975 enrolling individuals to test a Modified Vaccinia Virus Ankara Vaccine Expressing p53."
To what extent is the Modified Vaccinia Virus Ankara Vaccine Expressing p53 considered safe for patients?
"Considering that Modified Vaccinia Virus Ankara Vaccine Expressing p53 is in the early stages of clinical testing, our team at Power has rated its safety 1 out of 3 due to a dearth of evidence supporting efficacy and limited data concerning safety."
What disease indications is Modified Vaccinia Virus Ankara Vaccine Expressing p53 intended to treat?
"Modified Vaccinia Virus Ankara Vaccine Expressing p53 is a common treatment for malignant neoplasms and other illnesses including microsatellite instability high, unresectable melanoma, and disease progression following chemotherapy."
How many participants have joined this experiment thus far?
"Unfortunately, at this point in time, no further candidates can join the trial. Initially posted on June 14th 2016 and last updated March 17th 2022, it is now inactive for enrolment. Those searching for other studies may be interested to know that presently 9777 trials are actively admitting participants with melanoma and there are 975 trials recruiting patients regarding Modified Vaccinia Virus Ankara Vaccine Expressing p53."
What other explorations of Modified Vaccinia Virus Ankara Vaccine Expressing p53 have been conducted?
"Currently, 975 clinical trials of Modified Vaccinia Virus Ankara Vaccine Expressing p53 are live with 122 in Phase 3. Houston, Texas has several studies dedicated to this vaccine and 35804 locations worldwide operating related research experiments."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger